ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.557,27
-0,48%
S&P 500
5.367,26
0,27%
Dow Jones
38.952,72
0,17%
Euro vs US Dollar
1,08049
-0,79%
Bitcoin
70.589,30
-0,25%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Halozyme Therapeutics Incorporated (HALO)

  7. Halozyme Therapeutics Incorporated (HALO) News

HALO

Halozyme Therapeutics (HALO)

Halozyme Therapeutics Incorporated
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:HALO
DatumZeitQuelleÜberschriftSymbolFirma
06/06/202414h30PR Newswire (US)Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial OutlookNASDAQ:HALOHalozyme Therapeutics Incorporated
05/06/202422h05PR Newswire (US)Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery PlatformNASDAQ:HALOHalozyme Therapeutics Incorporated
04/06/202422h30PR Newswire (US)Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:HALOHalozyme Therapeutics Incorporated
22/05/202423h24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
22/05/202422h08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
21/05/202422h00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
21/05/202413h15PR Newswire (US)Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®NASDAQ:HALOHalozyme Therapeutics Incorporated
08/05/202414h30PR Newswire (US)Halozyme to Participate in Upcoming Investor ConferencesNASDAQ:HALOHalozyme Therapeutics Incorporated
07/05/202422h09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HALOHalozyme Therapeutics Incorporated
07/05/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HALOHalozyme Therapeutics Incorporated
07/05/202422h01PR Newswire (US)HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTSNASDAQ:HALOHalozyme Therapeutics Incorporated
25/04/202422h45PR Newswire (US)Mahesh Krishnan Elected to Halozyme's Board of DirectorsNASDAQ:HALOHalozyme Therapeutics Incorporated
23/04/202414h30PR Newswire (US)Halozyme to Report First Quarter 2024 Financial and Operating ResultsNASDAQ:HALOHalozyme Therapeutics Incorporated
04/03/202422h13Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:HALOHalozyme Therapeutics Incorporated
29/02/202400h49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
28/02/202422h07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
27/02/202423h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
27/02/202423h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
27/02/202423h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
27/02/202422h08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
27/02/202414h30PR Newswire (US)Halozyme to Participate in Upcoming Investor ConferencesNASDAQ:HALOHalozyme Therapeutics Incorporated
21/02/202400h59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
21/02/202400h55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
21/02/202400h53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
21/02/202400h49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
20/02/202422h07Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:HALOHalozyme Therapeutics Incorporated
20/02/202422h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HALOHalozyme Therapeutics Incorporated
20/02/202422h01PR Newswire (US)HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTSNASDAQ:HALOHalozyme Therapeutics Incorporated
16/02/202423h47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
16/02/202423h41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
 Showing the most relevant articles for your search:NASDAQ:HALO

Kürzlich von Ihnen besucht

TG
RHM
Rheinmetall
TG
DBK
Deutsche Bank
AMEX
XLE
Energy Select Sector SPDR
TG
MBG
MercedesBenz
COIN
SOLUSD
Solana
TG
432
Arbor Metals
TG
D7G
Nel ASA
FX
EURGBP
Euro vs Sterling
NYSE
MCD
McDonalds
USOTC
BASFY
BASF (QX)
NASDAQ
GOOGL
Alphabet
NYSE
XOM
Exxon Mobil
DBI
SDXP
SDAX
USOTC
DTEGY
Deutsche Telekom (QX)
AMEX
XLF
Financial Select Sector
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten